Watchlist Price Alert

Cue Biopharma Inc. (CUE)

NASDAQ: CUE · Real-Time Price · USD

0.78

0.01 (1.56%)

At close: May 09, 2025, 3:59 PM

0.78

-0.04%

After-hours: May 09, 2025, 04:00 PM EDT

1.56% (1D)

Bid	0.75
Market Cap	58.77M
Revenue (ttm)	9.29M
Net Income (ttm)	-40.67M
EPS (ttm)	-0.72
PE Ratio (ttm)	-1.08
Forward PE	-1.9
Analyst	Buy

Ask	0.8
Volume	90,374
Avg. Volume (20D)	171,052
Open	0.77
Previous Close	0.77
Day's Range	0.75 - 0.78
52-Week Range	0.45 - 1.99
Beta	1.51

About CUE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CUE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CUE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Cue Biopharma Inc. is scheduled to release its earnings on May 23, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+5.35%

Cue Biopharma shares are trading higher. Citizens ... Unlock content with Pro Subscription

1 month ago

-17.67%

Cue Biopharma shares are trading lower. The company reported FY24 financial results.

News

1 week ago · zacks.com

Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know

Cue Biopharma (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago · seekingalpha.com

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Cue Biopharma, Inc. (NASDAQ:CUE ) Business Update Call April 15, 2025 4:30 PM ET Company Participants Eric Ribner - LifeSci Advisors Dan Passeri - Chief Executive Officer Lucinda Warren - Chief Busine...

1 month ago · zacks.com

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.28 per share a year ago.